Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly.
Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain.
GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
GlaxoSmithKline’s Requip (ropinirole) was first launched in 1997 in certain European markets (France, UK) for Parkinson’s disease and restless legs syndrome. For Parkinson’s disease, it is approved for use in early patients as a monotherapy, or for advanced patients as an adjunct to levodopa therapy.
– Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on Requip including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for Requip for the top seven countries from 2012 to 2022.
– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of Requip performance
– Obtain sales forecast for Requip from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For more information visit: Radiant Insights
Corporate Sales Specialist, USA
Radiant Insights, Inc
Toll Free: 1-888-202-9519
Blog URL: http://www.esorics2010.org/